Raymond James analyst John Ransom downgraded Oak Street Health (OSH) to Market Perform from Outperform without a price target following CVS Health’s (CVS) announcement that it will buy the company for $10.6B. The firm is stepping to the sidelines as the stock has run up to the $35 price target as the remaining ~$4 will be a grind until the deal is ultimately closed, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OSH:
- Oak Street Health downgraded to Market Perform from Outperform at Raymond James
- CVS Health price target raised to $143 from $130 at Jefferies
- Oak Street Health downgraded to Hold from Buy at Jefferies
- Oak Street Health downgraded to Market Perform from Outperform at William Blair
- Oak Street Health downgraded to Hold from Buy at Canaccord